

## JANUS HENDERSON HORIZON FUND – BIOTECHNOLOGY FUND

A2 SGD ISIN LU1988887292

### Investment objective


The Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country.

### Performance (%)

| Returns                        | Cumulative |         |      | Annualised |        |        |         | Since inception |
|--------------------------------|------------|---------|------|------------|--------|--------|---------|-----------------|
|                                | 1 Month    | 3 Month | YTD  | 1 Year     | 3 Year | 5 Year | 10 Year |                 |
| A2 SGD (Net) with sales charge | -6.67      | 4.16    | 4.16 | 26.48      | 5.86   | —      | —       | 18.73           |
| Index                          | 0.50       | 3.93    | 3.93 | 9.91       | -1.19  | —      | —       | 7.24            |
| Sector                         | -1.53      | 4.49    | 4.49 | 11.34      | -4.90  | —      | —       | 3.80            |
| A2 SGD (Net)                   | -1.75      | 9.64    | 9.64 | 33.14      | 7.69   | —      | —       | 20.08           |

### Cumulative growth - SGD

13 Sep 2019 — 31 Mar 2024



| Calendar year | YTD at Q1 2024 | 2023  | 2022   | 2021  | 2020  | 2019 from 13 Sep |
|---------------|----------------|-------|--------|-------|-------|------------------|
| A2 SGD (Net)  | 9.64           | 21.37 | -4.32  | -1.96 | 59.12 | 15.70            |
| Index         | 3.93           | 2.87  | -10.58 | 2.03  | 24.26 | 13.38            |
| Sector        | 4.49           | 3.51  | -17.59 | -5.83 | 25.32 | 12.63            |

Performance is net of fees, with gross income reinvested. Performance figures of less than 1 year are not annualised. Source: at 31/03/24. © 2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.** For sales charge information, refer to Additional information on page 3.

### Fund details

|                    |   |
|--------------------|---|
| Inception date     | 10 December 2018                        |
| Total net assets   | \$261.80m                               |
| Asset class        | Equities                                |
| Domicile           | Luxembourg                              |
| Structure          | SICAV                                   |
| Base currency      | USD                                     |
| Index              | NASDAQ Biotechnology Total Return Index |
| Morningstar sector | Sector Equity Biotechnology             |

### Share class information

|                            |                   |
|----------------------------|-------------------|
| Inception date             | 13 September 2019 |
| NAV (SGD)                  | 22.98             |
| Distribution type          | Accumulation      |
| Historic yield             | 0.00%             |
| Currency                   | SGD               |
| Minimum initial investment | 2,500             |

The Historic Yield does not include any preliminary charge and investors may be subject to tax on their distributions.

### Portfolio management

|                          |                    |
|--------------------------|--------------------|
| Andy Acker, CFA          | Manager since 2018 |
| Daniel Lyons, Ph.D., CFA | Manager since 2018 |
| Agustin Mohedas, Ph.D.   | Manager since 2023 |

### Ratings

Overall Morningstar Rating™ ★★★★★  
As of 31/03/2024

For more information, refer to page 3.

**Characteristics**

|                                   |         |
|-----------------------------------|---------|
| Number of holdings: Equity issues | 83      |
| Weighted average market cap       | 37.04bn |
| Price-to-book ratio               | 4.96    |
| Price-to-earnings ratio           | 16.99   |

**Risk statistics (3 years)**

|                    | Fund  | Index |
|--------------------|-------|-------|
| Beta               | 1.06  | —     |
| Standard deviation | 21.36 | 15.62 |
| Sharpe ratio       | 0.23  | -0.23 |

**Top holdings as at 31/03/24 (%)**

|                          | Fund         |
|--------------------------|--------------|
| Vertex Pharmaceuticals   | 7.84         |
| Amgen                    | 7.76         |
| Avadel Pharmaceuticals   | 3.61         |
| Argenx                   | 3.42         |
| Sarepta Therapeutics     | 3.23         |
| Madrigal Pharmaceuticals | 2.96         |
| AstraZeneca              | 2.74         |
| Ascendis Pharma          | 2.68         |
| Vaxcyte                  | 2.62         |
| <b>Total</b>             | <b>41.30</b> |

References made to individual securities should not constitute or form part of any offer or solicitation to issue, securities mentioned in the report. Top holdings are disclosed on a quarterly basis.

**Market capitalisation of equity holdings (%)**

|               | Fund  | Index |
|---------------|-------|-------|
| >US\$100bn    | 22.78 | 30.00 |
| US\$10bn-50bn | 13.10 | 26.10 |
| US\$5bn-10bn  | 10.93 | 10.34 |
| US\$1bn-5bn   | 36.60 | 20.28 |
| <US\$1bn      | 13.74 | 5.05  |

**Sub-Sector allocation (%)**

|                        | Fund  | Index |
|------------------------|-------|-------|
| Biotechnology          | 68.12 | 58.33 |
| Pharmaceuticals        | 27.74 | 41.60 |
| Cash and Bonds         | 2.35  | —     |
| Medical Supplies       | 0.92  | —     |
| Medical Equipment      | 0.75  | —     |
| Health Care Facilities | 0.07  | —     |
| Index Derivatives      | 0.04  | —     |

**Top countries/regions (%)**

|                | Fund  | Index |
|----------------|-------|-------|
| United States  | 83.81 | 90.42 |
| United Kingdom | 4.55  | 4.64  |
| Belgium        | 3.42  | 1.33  |
| France         | 2.44  | 1.38  |
| China          | 1.79  | 0.81  |
| Australia      | 1.56  | —     |
| South Korea    | 0.07  | —     |
| Netherlands    | 0.01  | —     |

**Regions (%)**

|                  | Fund  | Index |
|------------------|-------|-------|
| North America    | 83.81 | 90.56 |
| Europe           | 5.87  | 3.95  |
| United Kingdom   | 4.55  | 4.64  |
| Emerging Markets | 1.79  | 0.85  |
| Pacific Region   | 1.63  | —     |

**Codes**

|           |              |
|-----------|--------------|
| ISIN      | LU1988887292 |
| Bloomberg | JAHHBAS      |
| SEDOL     | BJMXHR5      |

**Fees & charges (%)**

|                                |      |
|--------------------------------|------|
| Maximum initial sales charge   | 5.00 |
| Annual management charge (AMC) | 1.20 |

**Performance fee description**

20% of any returns that subject to a high water mark the share class achieves above the NASDAQ Biotechnology Total Return Index

|                                  |      |
|----------------------------------|------|
| <b>Total expense ratio (TER)</b> | 2.95 |
|----------------------------------|------|

Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time. For further explanation of charges please visit our Fund Charges page at [www.janushenderson.com](http://www.janushenderson.com). Performance fees may be charged before the Fund's outperformance target is reached. Performance fees are charged separately as a way of rewarding the investment manager for superior returns or for outperforming specified targets. A Performance Fee is accrued where the NAV outperforms the relevant Hurdle NAV (subject to a High Water Mark). For further explanation of the performance fee calculation methodology please see the relevant prospectus, available at [www.janushenderson.com](http://www.janushenderson.com). Under some circumstances initial charges may apply. Please refer to the Prospectus for more details.

## Additional fund information

Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. The performance fee described on page 2 will be applicable if the fund achieves a return in excess of the High Water Mark and the NASDAQ Biotechnology Total Return Index. Investors should refer to the prospectus for full details on performance fee where a performance fee is applicable. This is a Luxembourg SICAV Fund, regulated by the Commission de Surveillance du Secteur Financier (CSSF). Information relating to other currencies and fee structure can be found in the fund prospectus. Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk. Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations. To obtain our prospectus and any additional information please visit our website on: [www.janushenderson.com](http://www.janushenderson.com). Investment into the fund will acquire units/shares of the fund itself and not the underlying assets owned by the fund. Cash balances and exposures are based on settled and unsettled trades as at the reporting date. Performance with sales charge source: Janus Henderson. Investors, calculated on a NAV to NAV basis, net of 5.00% initial charge, with gross income reinvested at NAV price. Note: The performance calculation is based on a maximum initial sales charge of 5.00%. The actual initial sales charge paid by the unitholder may be different based on the discount, if any, applied by distributors. As such, the performance return may differ based on the discount, if any, applied by distributors. Refer to the prospectus for more details on shares classes offered. All ongoing charges stated are as per latest published report and accounts. Where the ongoing charges exceed the target outperformance relative to the benchmark the return is likely to be below the benchmark return, even when the Fund's outperformance target (before the deduction of charges) has been achieved. For funds which charge performance fees, investors should note that the total expense ratio includes the performance fees crystallised for the preceding performance period.

### Fund specific risks

When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies. The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider. Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result. Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses. If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified. The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events. The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations. If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates. Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses. The Fund may incur a higher level of transaction costs as a result of investing in less actively traded or less developed markets compared to a fund that invests in more active/developed markets.

### Source for fund ratings/awards

Overall Morningstar Rating™ is a measure of a fund's risk-adjusted return, relative to similar funds. Fund share classes are rated from 1 to 5 stars, with the best performers receiving 5 stars and the worst performers receiving a single star. Overall Morningstar Rating™ is shown for Janus Henderson share classes achieving a rating of 4 or 5. Ratings should not be taken as a recommendation. For more detailed information about Morningstar Ratings, including its methodology, please go to [www.global.morningstar.com/managerdisclosures](http://www.global.morningstar.com/managerdisclosures).

## Glossary

### Beta

Beta measures how a fund or security moves in relationship to the overall market. A market has a beta of 1. If the fund/security's beta is more than 1, it moves more than the market, while a beta lower than 1 means it moves to a lesser extent than the market. A negative beta could mean the fund/security moves in the opposite direction to the market.

### Historic Yield

The Historic Yield reflects distributions declared over the past 12 months as a percentage of the mid-market share price, as at the date shown.

### Price-to-book (P/B) ratio

A financial ratio used to value a company's shares. It is calculated by dividing a company's market value (share price) by the book value of its equity (value of the company's assets on its balance sheet). A P/B value <1 can indicate a potentially undervalued company or a declining business. The higher the P/B ratio, the higher the premium the market is willing to pay for the company above the book (balance sheet) value of its assets.

### Price-to-earnings (P/E) ratio

A popular ratio used to value a company's shares, compared to other stocks, or a benchmark index. It is calculated by dividing the current share price by its earnings per share.

### Sharpe ratio

This measures a portfolio's risk-adjusted performance. A high Sharpe ratio indicates a better risk-adjusted return. The ratio is designed to measure how far a portfolio's return can be attributed to fund manager skill as opposed to excessive risk taking.

### Standard deviation

A statistic that measures the variation or dispersion of a set of values/data. A low standard deviation shows the values tend to be close to the mean while a high standard deviation indicates the values are more spread out. In terms of valuing investments, standard deviation can provide a gauge of the historical volatility of an investment.

### Swaps

A derivative contract between two parties where pre-determined cash flows of two financial instruments are exchanged. Swaps can help to hedge risk and minimise uncertainty; for example currency swaps can be used to minimise foreign currency exposure.

### Weighted average market cap

The average market capitalisation of a holding, weighted by the size of that position in a portfolio or index.

**Janus Henderson**  
INVESTORS

FOR MORE INFORMATION PLEASE VISIT [JANUSHENDERSON.COM](http://JANUSHENDERSON.COM)

**ESG integration** is the practice of incorporating material environmental, social and governance (ESG) information or insights in a non-binding manner alongside traditional measures into the investment decision process to improve long term financial outcomes of portfolios. This product does not pursue a sustainable investment strategy or have a sustainable investment objective or otherwise take ESG factors into account in a binding manner. ESG related research is one of many factors considered within the investment process and in this material we seek to show why it is financially relevant. Issued in Singapore by Janus Henderson Investors (Singapore) Limited, licensed and regulated by the Monetary Authority of Singapore, Company Registration No. 199700782N. **This advertisement has not been reviewed by the Monetary Authority of Singapore.** The content herein is produced for information purposes only and does not constitute investment advice or as an offer to sell, buy or a recommendation for any security. Janus Henderson Investors is not responsible for any unlawful distribution of this document to any third parties, in whole or in part, and do not make any warranties with regards to the results obtained from its use. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of all information available from public sources. **Past performance does not predict future returns. Investing involves risk, including the possible loss of principal and fluctuation of value.** The Fund may employ investment techniques and instruments for investment purposes, such as trading in futures, options and swaps and other financial derivative instruments. This document has been prepared by Janus Henderson Investors (Singapore) Limited, the Singapore Representative of the Fund. The Fund is distributed by authorised distributors. The prospectus and Product Highlights Sheet ("PHS") of the Fund are available and may be obtained from the Singapore Representative's office and the authorized distributors' offices. Investors should read the prospectus and PHS before deciding whether to invest in the shares of the Fund. Investors are warned that they should only make their investments based on the most recent offering documents which contains information about fees, expenses and risks, which is available from appointed intermediaries, and which should be read carefully. An investment in the Fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. Investors are advised to consult your intermediary who will give you advice on the product suitability and help you determine how your investment would be consistent with your own investment objectives. The investment decisions are yours and an investment in the Fund may not be suitable for everyone. If in doubt, please contact your intermediary for clarification. Portfolio holdings are subject to change without notice. © 2024 Morningstar. All Rights Reserved. CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. ©Janus Henderson Group plc.